WO1994012631A1 - Peptide correspondant a l'exon 6 du gene cd44, anticorps specifiques dudit peptide et utilisation de ces anticorps dans le diagnostic des tumeurs - Google Patents
Peptide correspondant a l'exon 6 du gene cd44, anticorps specifiques dudit peptide et utilisation de ces anticorps dans le diagnostic des tumeurs Download PDFInfo
- Publication number
- WO1994012631A1 WO1994012631A1 PCT/GB1993/002394 GB9302394W WO9412631A1 WO 1994012631 A1 WO1994012631 A1 WO 1994012631A1 GB 9302394 W GB9302394 W GB 9302394W WO 9412631 A1 WO9412631 A1 WO 9412631A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- exon
- antibody
- peptide
- mak
- antibody according
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 91
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 93
- 238000003745 diagnosis Methods 0.000 title claims description 25
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims abstract description 137
- 102100032912 CD44 antigen Human genes 0.000 claims abstract description 135
- 238000000034 method Methods 0.000 claims abstract description 51
- 238000001514 detection method Methods 0.000 claims abstract description 17
- 150000001875 compounds Chemical class 0.000 claims abstract description 15
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 10
- 238000011503 in vivo imaging Methods 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 83
- 108090000623 proteins and genes Proteins 0.000 claims description 50
- 239000000047 product Substances 0.000 claims description 33
- 239000000427 antigen Substances 0.000 claims description 30
- 108091007433 antigens Proteins 0.000 claims description 30
- 102000036639 antigens Human genes 0.000 claims description 30
- 239000012634 fragment Substances 0.000 claims description 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 21
- 201000011510 cancer Diseases 0.000 claims description 19
- 108700028369 Alleles Proteins 0.000 claims description 16
- 230000004927 fusion Effects 0.000 claims description 15
- 239000002253 acid Substances 0.000 claims description 13
- 210000004408 hybridoma Anatomy 0.000 claims description 13
- 108020001507 fusion proteins Proteins 0.000 claims description 12
- 102000037865 fusion proteins Human genes 0.000 claims description 12
- 230000002163 immunogen Effects 0.000 claims description 12
- 230000027455 binding Effects 0.000 claims description 11
- 238000003018 immunoassay Methods 0.000 claims description 11
- 238000012360 testing method Methods 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 8
- 238000012216 screening Methods 0.000 claims description 6
- 239000007790 solid phase Substances 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 230000004048 modification Effects 0.000 claims description 5
- 238000012986 modification Methods 0.000 claims description 5
- 101150039504 6 gene Proteins 0.000 claims description 3
- 206010003445 Ascites Diseases 0.000 claims description 3
- 238000010171 animal model Methods 0.000 claims description 3
- 230000000890 antigenic effect Effects 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 230000013595 glycosylation Effects 0.000 claims description 3
- 238000006206 glycosylation reaction Methods 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims description 3
- 230000026731 phosphorylation Effects 0.000 claims description 3
- 238000006366 phosphorylation reaction Methods 0.000 claims description 3
- 239000002250 absorbent Substances 0.000 claims description 2
- 230000002745 absorbent Effects 0.000 claims description 2
- 238000010367 cloning Methods 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 210000000628 antibody-producing cell Anatomy 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 101150017002 CD44 gene Proteins 0.000 abstract description 17
- 230000009826 neoplastic cell growth Effects 0.000 abstract description 12
- 210000001124 body fluid Anatomy 0.000 abstract description 6
- 239000010839 body fluid Substances 0.000 abstract description 6
- 230000002018 overexpression Effects 0.000 abstract description 6
- 238000004458 analytical method Methods 0.000 abstract description 5
- 239000002699 waste material Substances 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 70
- 239000000523 sample Substances 0.000 description 68
- 238000003752 polymerase chain reaction Methods 0.000 description 37
- 210000000481 breast Anatomy 0.000 description 35
- 239000013615 primer Substances 0.000 description 29
- 101800001466 Envelope glycoprotein E1 Proteins 0.000 description 28
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 28
- 210000001165 lymph node Anatomy 0.000 description 28
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 27
- 238000010804 cDNA synthesis Methods 0.000 description 26
- 108020004635 Complementary DNA Proteins 0.000 description 23
- 239000002299 complementary DNA Substances 0.000 description 23
- 230000014509 gene expression Effects 0.000 description 23
- 235000018102 proteins Nutrition 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 20
- 108700024394 Exon Proteins 0.000 description 18
- 206010027476 Metastases Diseases 0.000 description 17
- 150000001413 amino acids Chemical class 0.000 description 17
- 210000002700 urine Anatomy 0.000 description 17
- 210000001072 colon Anatomy 0.000 description 16
- 230000001394 metastastic effect Effects 0.000 description 16
- 206010061289 metastatic neoplasm Diseases 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 239000000872 buffer Substances 0.000 description 15
- 230000001613 neoplastic effect Effects 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 210000004881 tumor cell Anatomy 0.000 description 13
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 12
- 241000588724 Escherichia coli Species 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 11
- 210000000265 leukocyte Anatomy 0.000 description 11
- 230000009401 metastasis Effects 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 11
- 238000005406 washing Methods 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 10
- 201000009030 Carcinoma Diseases 0.000 description 10
- 102000014914 Carrier Proteins Human genes 0.000 description 10
- 108010078791 Carrier Proteins Proteins 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 229940098773 bovine serum albumin Drugs 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 208000026310 Breast neoplasm Diseases 0.000 description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 239000008363 phosphate buffer Substances 0.000 description 8
- 239000000020 Nitrocellulose Substances 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 238000010276 construction Methods 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000003211 malignant effect Effects 0.000 description 7
- 229920001220 nitrocellulos Polymers 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- 229910001868 water Inorganic materials 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 6
- 239000012980 RPMI-1640 medium Substances 0.000 description 6
- 238000000211 autoradiogram Methods 0.000 description 6
- 229960002685 biotin Drugs 0.000 description 6
- 239000011616 biotin Substances 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 210000003932 urinary bladder Anatomy 0.000 description 6
- 239000003155 DNA primer Substances 0.000 description 5
- 208000007659 Fibroadenoma Diseases 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 235000020958 biotin Nutrition 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 230000000683 nonmetastatic effect Effects 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 239000002987 primer (paints) Substances 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 239000012064 sodium phosphate buffer Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 4
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 4
- 206010005003 Bladder cancer Diseases 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 102100034349 Integrase Human genes 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 4
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 201000003146 cystitis Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 150000007523 nucleic acids Chemical group 0.000 description 4
- -1 nucleotide triphosphates Chemical class 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 210000004989 spleen cell Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 201000005112 urinary bladder cancer Diseases 0.000 description 4
- JKHVDAUOODACDU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCN1C(=O)C=CC1=O JKHVDAUOODACDU-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000034454 F12-related hereditary angioedema with normal C1Inh Diseases 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 238000002123 RNA extraction Methods 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 238000007413 biotinylation Methods 0.000 description 3
- 230000006287 biotinylation Effects 0.000 description 3
- 208000011803 breast fibrocystic disease Diseases 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 239000013522 chelant Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229960005542 ethidium bromide Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 208000016861 hereditary angioedema type 3 Diseases 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 230000008883 metastatic behaviour Effects 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101100059521 Homo sapiens CD44 gene Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N Hypoxanthine Natural products O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 108091092328 cellular RNA Proteins 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 239000000562 conjugate Substances 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 229960004198 guanidine Drugs 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 230000002637 immunotoxin Effects 0.000 description 2
- 239000002596 immunotoxin Substances 0.000 description 2
- 231100000608 immunotoxin Toxicity 0.000 description 2
- 229940051026 immunotoxin Drugs 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- 238000010841 mRNA extraction Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000863 peptide conjugate Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 238000007790 scraping Methods 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ZPGDWQNBZYOZTI-SFHVURJKSA-N (2s)-1-(9h-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ZPGDWQNBZYOZTI-SFHVURJKSA-N 0.000 description 1
- REITVGIIZHFVGU-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](COC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 REITVGIIZHFVGU-IBGZPJMESA-N 0.000 description 1
- FODJWPHPWBKDON-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 FODJWPHPWBKDON-IBGZPJMESA-N 0.000 description 1
- CBPJQFCAFFNICX-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 CBPJQFCAFFNICX-IBGZPJMESA-N 0.000 description 1
- VCFCFPNRQDANPN-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCC)C(O)=O)C3=CC=CC=C3C2=C1 VCFCFPNRQDANPN-IBGZPJMESA-N 0.000 description 1
- QWXZOFZKSQXPDC-NSHDSACASA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C)C(O)=O)C3=CC=CC=C3C2=C1 QWXZOFZKSQXPDC-NSHDSACASA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
- AGNGYMCLFWQVGX-AGFFZDDWSA-N (e)-1-[(2s)-2-amino-2-carboxyethoxy]-2-diazonioethenolate Chemical compound OC(=O)[C@@H](N)CO\C([O-])=C\[N+]#N AGNGYMCLFWQVGX-AGFFZDDWSA-N 0.000 description 1
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- MQOMKCIKNDDXEZ-UHFFFAOYSA-N 1-dibutylphosphoryloxy-4-nitrobenzene Chemical compound CCCCP(=O)(CCCC)OC1=CC=C([N+]([O-])=O)C=C1 MQOMKCIKNDDXEZ-UHFFFAOYSA-N 0.000 description 1
- DNITTWABAYHZQU-UHFFFAOYSA-N 2-(2,5-dioxopyrrol-1-yl)propanamide Chemical compound NC(=O)C(C)N1C(=O)C=CC1=O DNITTWABAYHZQU-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- CKRJGDYKYQUNIM-UHFFFAOYSA-N 3-fluoro-2,2-dimethylpropanoic acid Chemical compound FCC(C)(C)C(O)=O CKRJGDYKYQUNIM-UHFFFAOYSA-N 0.000 description 1
- ACUIFAAXWDLLTR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)butanoic acid Chemical compound C1=CC=C2C(COC(=O)NCCCC(=O)O)C3=CC=CC=C3C2=C1 ACUIFAAXWDLLTR-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 101000583086 Bunodosoma granuliferum Delta-actitoxin-Bgr2b Proteins 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 102000027791 CD44 antigen Human genes 0.000 description 1
- 108091016585 CD44 antigen Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 101000713211 Colocasia esculenta Mannose-specific lectin TAR1 Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 208000006402 Ductal Carcinoma Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 206010014666 Endocarditis bacterial Diseases 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 208000000571 Fibrocystic breast disease Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102100028084 Hyaluronan and proteoglycan link protein 1 Human genes 0.000 description 1
- 101710191341 Hyaluronan and proteoglycan link protein 1 Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010092694 L-Selectin Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical group CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 102000010836 Lymphocyte Homing Receptors Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 206010027459 Metastases to lymph nodes Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101000868277 Rattus norvegicus CD44 antigen Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010042135 Stomatitis necrotising Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 206010047697 Volvulus Diseases 0.000 description 1
- XPIVOYOQXKNYHA-RGDJUOJXSA-N [(2r,3s,4s,5r,6s)-3,4,5-trihydroxy-6-methoxyoxan-2-yl]methyl n-heptylcarbamate Chemical compound CCCCCCCNC(=O)OC[C@H]1O[C@H](OC)[C@H](O)[C@@H](O)[C@@H]1O XPIVOYOQXKNYHA-RGDJUOJXSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 238000007818 agglutination assay Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 208000009361 bacterial endocarditis Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 201000003149 breast fibroadenoma Diseases 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000011072 cell harvest Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000000739 chaotic effect Effects 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 238000002967 competitive immunoassay Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- NLEBIOOXCVAHBD-QKMCSOCLSA-N dodecyl beta-D-maltoside Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLEBIOOXCVAHBD-QKMCSOCLSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical group NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
- 210000004524 haematopoietic cell Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 102000048851 human CD44 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 201000007119 infective endocarditis Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 201000007647 intestinal volvulus Diseases 0.000 description 1
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 150000002669 lysines Chemical class 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 208000011645 metastatic carcinoma Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- CMWYAOXYQATXSI-UHFFFAOYSA-N n,n-dimethylformamide;piperidine Chemical compound CN(C)C=O.C1CCNCC1 CMWYAOXYQATXSI-UHFFFAOYSA-N 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 201000008585 noma Diseases 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 238000009595 pap smear Methods 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 239000013034 phenoxy resin Substances 0.000 description 1
- 229920006287 phenoxy resin Polymers 0.000 description 1
- 238000004987 plasma desorption mass spectroscopy Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70585—CD44
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70585—CD44
Definitions
- the present invention is concerned with using expression of the CD44 gene or part of the CD44 gene to investigate neoplasia. Such investigation includes
- the invention provides a simple method for carrying out routine screening for neoplasia using
- the human CD44 gene codes for a family of variably glycosylated cell surface proteins of different sizes, the numerous functions of which are not yet fully established, but which share epitopes recognised by the CD44 monoclonal antibody (mAb) . It is known to consist of a standard portion which is expressed in haemopoietic cells and many other cell types and into which the products of additional exons may be spliced in various combinations to produce different proteins. This is a well recognised mechanism in eukaryotes for producing several often functionally unrelated proteins from the same gene, and is known as alternative splicing.
- mAb monoclonal antibody
- CD44 isoforms Two common CD44 isoforms have so far been purified and characterised ( ⁇ tamenkovic et al. 1989), namely i) a 90kD form consisting of a central 37kD core which is heavily glycosylated and ii) a 180kD form which has 135 extra amino acids inserted into the proximal extra-membrane domain and is even more heavily glycosylated.
- Immuno-cytochemical and immuno- precipitation studies have shown that both are widely distributed in many different cells and tissues.
- the former is known as the haemopoietic or standard form which is present on circulating leukocytes, bone marrow cells and numerous other cell types.
- the other known as the epithelial variant, is detectable on several epithelial cell types. Both are believed to function as receptors mediating homotypic and heterotypic adhesive interactions, attaching cells to each other or to adjacent extracellular scaffolding.
- the present invention results from a surprising discovery resulting from studies examining the expression of various parts of the CD44 gene in fresh tissue and body fluid samples from patients with tumours of the breast and colon and from their metastases.
- the results indicate sharp and clear differences in CD44 expression between tissues from i) metastatic (malignant) tumours, ii) non- metastatic locally invasive tumours and benign tumours and iii) normal tissue.
- the distinction between groups i) and ii) is important for judgment of therapy and that between groups ii) and iii) is important for early diagnosis and screening.
- Part of this invention forms the subject of our International patent application PCT/GB93/01520 filed 20 July 1993, which provides in one aspect a method of diagnosis of neoplasia, which method comprises analysing the expression of the CD44 gene in a sample.
- that application provides a method of assaying a sample for products of the CD44 gene or part thereof which method comprises making cDNA from messenger RNA (mRNA) in the sample, amplifying portions of the complementary DNA (cDNA) corresponding to the CD44 gene or part thereof and detecting the amplified cDNA, characterised in that the amplified cDNA is used in diagnosis of neoplasia.
- mRNA messenger RNA
- cDNA complementary DNA
- diagnosis of neoplasia may refer to the initial detection of neoplastic tissue or it may be the step of distinguishing between metastatic and non- metastatic tumours. References to the term "diagnosis" as used herein are to be understood accordingly.
- the method is particularly applicable to the diagnosis of solid tumours particularly malignant tumours e.g. carcinomas.
- the sample on which the assay is performed is preferably of body tissue or body fluid; and not of cells cultured in vitro.
- the sample may be a small piece of tissue or a fine needle aspirate (FNA) of cells from a solid tumour.
- FNA fine needle aspirate
- it may be a sample of blood or urine or another body fluid, a cervical scraping or a non- invasively obtained sample such as sputum, urine or stool.
- the cDNA may be detected by use of one or more labelled specific oligonucleotide probes, the probes being chosen so as to be capable of annealing to part of the amplified cDNA sequence.
- labelled oligonucleotide primers and/or labelled mononucleotides could be used.
- detectable labels which can be employed, including radiolabels.
- FIGS 1 to 5 are autoradiographs showing the results of various experiments reported below.
- Figure 6 is a map of the CD44 gene showing exons, probes and primers. The numbering of the exons corresponds to that used by G. R. Screaton et al. 1992) ,
- Figure 7 is the nucleic acid sequence of Exon 6 (shown in Figure 6), the corresponding amino acid sequence being also shown, and
- Figure 8 is a set of autoradiographs showing the results of another experiment.
- Figure 9 is the DNA sequence of HIV2(gp32)- CD44 exon 6 fusiongene.
- Figure 10 is the protein sequence of
- HIV2(gp32) -CD44 exon 6 fusionantigen HIV2(gp32) -CD44 exon 6 fusionantigen.
- Figure 6 is a map of the CD44 gene showing exons 6 to 14.
- the basic or standard protein can theoretically be modified by the insertion of transcripts from any, some, or all of these 9 extra exons.
- Exon 6 was unknown at the priority date of this patent application, and constitutes a further aspect of the invention.
- Exon 6 is over-expressed in tumours but not in normal tissues, and is located in the vicinity of exons 7 to 9. The sequence of exon 6 is given in
- Figure 7 It contains 129 base pairs and is flanked on the 5 ' -side by the standard CD44 sequence, and on the 3 '-side usually by exon 7.
- Exon 6 In contrast to Exons 9 to 11, the products of Exon 6 (the newly-sequenced Exon) are only barely detectable in samples of normal tissues. This suggests that Exon 6 will be of particular value in the diagnosis of neoplasia.
- nucleic acid sequence of Exon 6 as shown in Figure 7 provides as new compounds, the nucleic acid sequence of Exon 6 as shown in Figure 7, characteristic fragments thereof, sequences which are degenerated and/or represent allele variations, the homologous nucleic acid sequences, and probes, primers and other reagents capable of hybridising with the sequences or homologues .
- probes, primers and other reagents capable of hybridising with the sequences or homologues .
- the peptide sequence corresponding to CD44 exon 6 as shown in Figure 7, its allele variations and secondary modifications thereof and characteristic fragments thereof can be used the generate antibodies useful for the in vitro and in vivo diagnosis.
- Said antibodies are specific to the peptide corresponding to CD44 exon 6 as shown in Figure 7, its allele variations and secondary modifications thereof and characteristic fragments thereof i.e. these antibodies bind to this peptide and possess a low cross-reactivity towards other related CD44 proteins and other proteins.
- Said antibodies may be monoclonal or polyclonal.
- the antibodies may be generated by using the entire peptide sequence corresponding to CD44 exon 6 as shown in Figure 7 as an antigen or by using short peptides preferebly of a minimum length of six amino acids encoding portions of the peptide sequence corresponding to CD44 exon 6, as antigens.
- the peptides used as antigens can be produced recombinantely or chemically by methods known in the art.
- the peptide antigens according to the invention can for example be synthesized according to Merryfield, JACS 85 (1964), 2146.
- these peptides can be coupled to a carrier molecule for example keyhole limpet hemocyanin (KLH) or bovine serum albumin (BSA) .
- KLH keyhole limpet hemocyanin
- BSA bovine serum albumin
- a biotinylation is required this can for example be carried out according to PNAS USA 80 (1983), 4045.
- a fusion gene of CD44 exon 6 or its allele variations with a gene which possess a high expression level in this host.
- a part of the gene encoding for the protein gp 32 of HIV 2 is suitable for E. coli.
- a fusion protein which possesses as a part the peptide sequence according to Exon 6 or its allele variations is obtained.
- polyclonal antibodies directed against the peptide sequence corresponding to CD44 exon 6, its allele variations and secondary modifications thereof and characteristic fragments are prepared by injection of suitable laboratory animal with an effective amount of a peptide or antigenic component, collecting serum from the animal, and isolating specific antibodies by any of the known immuno absorbent techniques. Although the polyclonal antibodies produced by this method are utilizable in any type of immunoassay, they are generally less favoured because of the potential heterogeneity.
- the use of monoclonal antibodies in the in vitro diagnostic test is particularly preferred because large quantities of antibodies all of similar specificity may be produced.
- the preparation of hybridoma cell lines for monoclonal antibody production is done by fusion of an immortal cell line and the antibody producing lymphocytes. This can be done by techniques which are well known in the art (see for example Harlow, E. and Lane, D., Antibodies: A Laboratory Manual, Cold Spring Harbour Press 1988, Bessler et al. Immunobiol. 170 (1985), 239 - 244, Jung et al., Angew. Chemie 97 (1985), 883 or Cianfriglia et al., Hybridoma Vol. 2, (1983), 451 - 457).
- a synthetic peptide corresponding to amino acids 9 - 23 for MAK ⁇ CD44>M- 2.42.3 a synthetic peptide corresponding to amino acids 29 - 43 and for MAK ⁇ CD44>M-4.3.16 a synthetic peptide corresponding to amino acids 1 - 13 of the CD44 exon 6 peptide having the amino acid sequence shown in Figure 7 was used.
- the antibody produced by the cell line MAK ⁇ CD44>M-1.1.12 shows a specificity to tumor tissue of lung, colon and bladder and for cells of the cell line ZR75-1 (human breast carcinoma - ATCC CRL 1500) as detected by immunohistochemistry. A specific reaction means that a strong reaction is observed with the tumor tissue whereas normal tissue shows only a weak reaction.
- the antibody produced by the cell line MAK ⁇ CD44>M-4.3.16 shows specificity towards tumor tissue of colon and ZR75-1 cells.
- the presence of the CD 44 protein or the peptide sequence according to CD44 exon 6 in a sample can be detected utilizing antibodies prepared as discribed above either monoclonal or polyclonal in virtually any type of immunoassay.
- a wide range of immunoassay techniques are available as can be seen by reference to Harlow, et al. (Antibodies: A Laboratory Manual, Cold Spring Harbour Press 1988). This of course includes both single-site and two-site, or "sandwich" of the non-competitive types, as well as competitive binding assays.
- Sandwich assays are among the most useful and commonly used assays. A number of variations of the sandwich assay technique exist, and all are intended to be encompassed by the present invention.
- radio immunoassays examples include radio immunoassays, enzyme immunoassays or immunofluorescent assays such as FPIA or electrochemilumineszent assays, immunoassays using direct labels such as dye particles (e.g. gold sol particles), homogeneous immunoassays such as CEDIA or EMIT or turbidimetric and nephelometric methods such as latex particle agglutination assays.
- dye particles e.g. gold sol particles
- homogeneous immunoassays such as CEDIA or EMIT or turbidimetric and nephelometric methods such as latex particle agglutination assays.
- turbidimetric and nephelometric methods such as latex particle agglutination assays.
- antibodies could for example be prepared by using two different synthetic peptides as immunogens corresponding to different characteristic fragments of the peptide corresponding to CD44 exon 6. It is also possible to use only one antibody according to the invention in a sandwich assay. The other antibody could be an antibody to the other peptides corresponding to other CD44 exons or to the standard form of CD44. Such antibodies are known in the art.
- the CD44 protein could be detected in its native form.
- the CD44 protein is denatured prior to or during its detection because some of the antibodies according to the invention preferably bind to epitopes which are linear or which are hidden within the CD44 molecule in its native form.
- a denaturation method any method known in the art such as treatment with detergent or chaotropic agents is suitable.
- the adsorption of the CD44 molecule to a solid phase leads to a partial denaturation which is sufficient for the binding of the antibody.
- CD44 proteins are expressed on most 5 cell types it was found that with the use of the antibodies according to the invention a differentiation between tumor tissue and normal tissue is possible in most cases.
- the antibodies therefore could be used in cancer diagnosis.
- the antibodies could be used in cancer diagnosis.
- the antibodies could be used in cancer diagnosis.
- the antibodies could be used in cancer diagnosis.
- 25 invention can also be used as a standard compound in immunological tests for the quantitative determination of CD 44.
- the invention therefore in addition concerns the use of the peptide antigens according to the invention as a standard in an immunological test for
- CD 44 the determination of CD 44.
- the peptides according to the invention can be advantageous to bind several peptides according to the invention with the same or different sequences to a carrier J molecule.
- 35 also be used as a binding partner for the antibody according to the invention in a competitive immunoassay.
- the peptides are labeled or bound to a solid phase directly or indirectly via two specific binding partners such as (strept)avidin/biotin by methods known in the art.
- Another aspect of the invention is a test kit containing at least one antibody which is directed against the peptide corresponding to CD44 exon 6 having the amino acid sequence as shown in Figure 7, its allele variations or secondary modifications thereof or characteristic fragments thereof among the other compounds which are necessary for the immunoassay such as buffers, detergents, stabilizers, solid phases etc. If required the peptide antigens according to the invention as a standard could also be included.
- this invention provides a means for therapy and in vivo imaging of tumours.
- Agents useful for this can be manufactured according to the state of the art.
- the data obtained from studies examining the expression of various parts of the CD44 gene m samples from patients with malignant diseases surprisingly show a significant overexpression of exon 6 of the variable part of CD44.
- the relative abundance of CD44 splice variants containing exon 6 in malignant tumours as compared to normal tissue and the increased amount of CD44 proteins containing the peptide sequence encoded by exon 6 on the surface of tumour cells as compared to normal tissue opens the possibility to use the exon 6 encoded peptide sequence as a tumour specific antigen for therapy, diagnosis both in vivo and in vitro, and in vivo imaging.
- monoclonal antibodies (Kohler and Milstem (1975), Nature 156, 495-497) or their derivatives will be used for diagnostic and therapeutic purposes.
- monoclonal antibodies to epitopes encoded by exon 6 of CD44 are provided.
- data are presented, showing selective binding of these antibodies to tumour cells.
- the antibodies according to the invention recognize the peptide corresponding to CD44 exon 6 having the ammo acid sequence shown in Fig. 7, its allel variations and phosphorylation and glycosylation products and characteristic fragments thereof.
- Such antibodies are specific to the peptide corresponding to CD44 exon 6 also m the presence of other peptides which correspond to other CD44 exons.
- the antibody according to the invention binds only to a little extent to proteins other than the protein encoded by exon 6. This unspecific binding must be so little as to ensure t ⁇ t no considerable damage will be caused to healthy cells when the antibodies according to the invention are used for tumour therapy or in vivo diagnosis.
- the antibodies can be used as whole antibodies, fragments thereof (e.g. Fv, (Fv) 2 , Fab, Fab ' , F(ab) 2 , chimeric, humanized or human antibodies as long as they are binding the exon 6 protein in a suitable manner. Short-chain antibody fragments containing only the CDR regions or parts thereof conferring the specific binding to the exon 6 peptide are also suitable, especially if the antibody is a labelled one.
- the antibodies can be used as a whole for therapy of malignant diseases (Hale et al. , Lancet 2 (1988) 1394-1399; Cobbold et al. , Prog. Clin. Biol. Res. (1990) 333,139-151).
- the antibody or part of it is conjugated or translationally fused to a toxin molecule (immunotoxin) , thus effecting specific killing of tumour cells (Brinkmann et al.
- bispecif c antibodies are used for tumour therapy (Bonmo et al. (1992), BFE 9, 719-723), which may be constructed by in vitro reassociation of polypeptide chains, by hybrid hybridoma generation or by construction of diabodies (Holliger et al. (1993), Proc. Natl. Acad. Sci. USA 90, 6444-6448; Holliger and Winter (1993), Current Opm. Biotechnol. 4, 446-449).
- tumours including carcinomas of the respiratory, gastrointestinal and urogemtal system as well as ocular and skin cancers (Profio M988), Proc. Soc. Photoopt. Instr. Eng. 907, 150-156; Jiang et al. (1991), J. Natl. Cancer Inst. 83, 1218-1225).
- antibodies which resemble as closely as possible antibodies of human origin (Glassy and Dillman (1988), Mol. Biother. 1, 7-13). Such antibodies are, for example, chimeric or humanized (CDR-grafted) antibodies. Such antibodies usually are manufactured from a rodent monoclonal antibody (see e.g. for review: Morrison (1992), Annu. Rev. Immunol. 10, 239-265; Winter and Milstein (1991), Nature 349, 293-299) . In a specifically preferred embodiment of the invention, tumour specific human antibodies (Borrebaeck et al. (1988), Proc. Natl. Acad. Sci. USA 85, 3995-3999; Borrebaeck (1988), Immunol.
- Today 9, 355-359) are used for therapeutic purposes.
- ADCC effector functions
- CDC Bruggemann et al. , J. Exp. Med. 166 (1987) 1357-1361.
- a human lsotype IgG 1 antibody is used.
- the antibody according to the invention it is preferred to couple the antibody according to the invention to a toxin, such as, for example, Pseudomonas exotoxm, Diphtheria toxin or other toxins (FitzGerald and Pastan (1989)). It is also preferred to couple the antibodies to chemotherapeutics, such as, for instance doxorubicin, or to radioactively labelled substances which have a cytotoxic effect.
- a toxin such as, for example, Pseudomonas exotoxm, Diphtheria toxin or other toxins (FitzGerald and Pastan (1989)
- chemotherapeutics such as, for instance doxorubicin
- radioactively labelled substances which have a cytotoxic effect.
- fluorescent substances are also preferred.
- the therapeutic compounds of this invention may be administered parenterally, such as mtravascularly, intraperitoneally, subcutaneously, mtramuscuiarily, using forms known in the pharmaceutical art.
- the active drug components of the present invention are used m liquid, powdered or lyophilized form and may be combined with a suitable diluent or carrier, such as water, a saline, aqueous dextrose, aqueous buffer, and the like. Preservatives may also be added.
- the compounds of the present invention are formulated into pharmaceutically acceptable dosage forms by conventional methods known to those skilled in the art.
- the compounds may also be formulated using pharmacologically acceptable acid or base addition salts.
- the compounds or their salt may be used in a suitable hydrated form.
- a non-toxic but therapeutically effective quantity of one or more compounds of this invention is employed in any treatment.
- the dosage regimen for treating is selected in accordance with a variety of factors including the type, age, weight, sex and medical condition of the patient, type of tumour, the route of administration and the particular compound employed in the treatment.
- a physician of ordinary skill can readily determine and prescribe the effective amount of the drug required regarding known antibody therapy approaches (Hale (1988), Cobbold (1990)). In so proceeding, the physician could employ relatively low doses at first, and subsequently, increased dose until a maximum response is obtained.
- the chaotic over-expression of multiple spliced variants of the CD44 gene in tumours implies that a particular exon may or may not be over-expressed (or expressed at all) by a particular tissue sample.
- An immunoassay using an antibody to the peptide expressed by any single exon may therefore give misleading results.
- This invention therefore includes use, for the immunological diagnosis of neoplasia, of a mixture of antibodies to two or more, and preferably to all nine, of the CD44 exons.
- transcripts from exon 10/11 m normal tissues indicate that this exon is not exclusively concerned with metastatic activity, even though there is marked increase in the number and signal intensity of bands hybridising with radiolabelled probe E4 in the PCR products from tumours capable of metastasis. Other supporting events are therefore believed to be required for CD44 exon 10/11 expression to result in metastatic behaviour. Nevertheless, the observation that transcripts from this exon were over-expressed in samples from metastatic tumours promises to be a very useful indicator of prognosis.
- RNA extraction from tissue samples was performed according to the method described by Chomizynski and Sacchi (1987). Extraction from fluid samples was by use of the Microfasttrack kit marketed by Invitrogen. cDNA synthesis and subsequent amplification by the polymerase chain reaction (PCR) was performed using the SuperscriptTM preamplification system (BRL Life Technologies Inc., Middlesex, UK) with buffers and reagents supplied in this kit. In brief, this involves an initial step of first strand cDNA synthesis with reverse transcriptase, using sample RNA as the template and supplied nucleotide triphosphates.
- PCR polymerase chain reaction
- P4 5 ' GATGCCAAGATGATCAGCCATTCTGGAAT P1 is located with its origin 324bp upstream from the insertion site in the standard CD44 molecule (between nucleotides 782 and 783 in the sequence published by Stamenkovic et al . 1989) and P4 is 158bp downstream of this site.
- These primers produce a PCR fragment of 482bp if a sample expresses standard CD44 (so-called haemopoietic CD44), 878bp for the epithelial form of CD44 and several other bands, if a sample contains alternatively spliced transcripts.
- PBL peripheral blood leukocytes
- ammonium chloride buffer (1ml packed cells to 50mls lysis buffer) and subsequent centrifugation 15 minutes later.
- the white cell pellet was divided into 4 tubes which were seeded respectively with O ⁇ l, 1 ⁇ l, 1O ⁇ l and 100 ⁇ l of a suspension of HT29 colon carcinoma cells (5000 cells per ml) .
- Total RNA was then extracted and each tube yielded approximately 20 ⁇ g.
- cDNA synthesis was performed, as described above on 4 ⁇ g aliquots of the RNA obtained from each tube representing 0, 1, 10 and 100 tumour cells per aliquotted sample respectively.
- the PCR was performed on these samples and on positive (tumour cells only) and negative (no DNA) controls using primers D1 and D5 which were designed by us to anneal specifically to exons 7 and 14 in Figure 6.
- primers D1 and D5 were designed by us to anneal specifically to exons 7 and 14 in Figure 6.
- primers P1 and P4 for this specific purpose because the majority of these would be soaked up by annealing to the standard portion of the gene.
- PCR cycle parameters, blotting, probing and washing conditions were as described above.
- the oligonucleotide sequence used for probing was ⁇ 2 P labelled E4.
- primers (P1 and P4) amplify across the - 2 1 -
- Primer P1 5 ' -GACACATATTGCTTCAATGCTTCAGC (458-484)
- Primer P2 5 '-CCTGAAGAAGATTGTACATCAGTCACAGAC (488-518)
- Primer P3 5 ' -TGGATCACCGACAGCACAGAC (746-767)
- Primer P4 5 ' -GATGCCAAGATGATCAGCCATTCTGGAAT (912-941) for standard part (Stamenkovic 1989)
- Primer E1 5 ' -TTGATGAGCACTAGTGCTACAGCA
- Primer E2 5 ' -CATTTGTGTTGTTGTGTGAAGATG Primer E3-5 ' -AGCCCAGAGGACAGTTCCTGG (534-554)
- Primer E4 5 '-TGAGATTGGGTTGAAGAAATC (558-578)
- Primer E5 5 ' -TCCTGCTTGATGACCTCGTCCCAT (585-608)
- E1 and E2 are on exon 6.
- Fresh tissue samples 0.5-1 cm in diameter were obtained from surgical resection specimens or at autopsy. All samples used in this work were obtained from the residue of tissue remaining after diagnostic samples had been taken, and which would otherwise have been discarded. The samples were snap- - 25 -
- cDNA was synthesised with viral reverse transcriptase using 5 ⁇ g of total cellular RNA as template, followed by PCR with Primer P1 and Primer P4. PCR amplification, electrophoresis and hybridisation were performed under standard conditions.
- the oligonucleotide probe for Exon 6 products is very effective in distinguishing neoplastic from non- neoplastic samples, but not significantly more sensitive than E4, at least on samples from solid tissues, but is possibly useful for detecting organ of origin of a disseminating metastatic cell or an established metastasis.
- the same filters were stripped and hybridised with P2 probe to show that all samples, including normal tissues, produced the standard portion of CD44. This confirmed that the differences observed between the results obtained with normal and tumour samples, probed with E2 and E4, were not due to unequal loading of PCR products.
- the cumulative results are summarised in Table 3 which indicates that these changes are seen in a wide range of common cancers.
- cytological examination Another 1 ml of urine was checked by Fluorescein diacetate-ethidium bromide staining to assess the viability of cells in the sample. The remainder of the urine was centrifuged at 2000rpm for 10 minutes and the cell pellet was kept at -70'C until use. mRNA extraction was performed with oligo dT cellulose tablets (invitrogen) . cDNA was synthesised with AMV reverse transcriptase (Invitrogen) .
- the completed cDNA solution was divided equally into two tubes, one being for PCR with E1 and E5, to amplify the particular cDNA transcript, which we have found to be of diagnostic value and the other for PCR with P1 and P4 to amplify the standard form of CD44, with or without all splice variants, as an internal control.
- Equal volumes of PCR products were loaded in each lane of a 1.2% agarose gel and stained with ethidium bromide. If the cells in the urine were to be expressing all the Exons from Exon 6 to Exon 14, it was predicted that with the current PCR protocol, using primers E1 and E4, should produce a 735 bp band. There is no band in tracks containing cDNA from normal urine or that of patients with non-neoplastic cystitis (lanes 1-8) but a clear 735 band is seen in all urine samples from patients with bladder cancer (lanes 9-16) when PCR was performed with primer E1 and E5 (upper panel) .
- Lanes 1-4 normal urine. Lanes 5-8: cystitis urine. Lanes 9-16: from patients 1-8 with bladder cancer.
- the inventors have explored the procedures needed to ensure the routine RT-PCR detection of abnormal CD44 gene activity in small clinical samples containing tumour cells. If a tissue sample is divided into aliquots, half of which are frozen in liquid nitrogen immediately and the remainder of which are left at ambient temperature, one can show how the ability to detect CD44 splice variants declines with time and with mode of specimen handling. Fresh samples submitted to mRNA extraction within half an hour of excision give the most reliable results and there is a gradual decline in quality over the next few hours if the fresh tissue is left at ambient temperature. If the sample is first snap frozen, the results obtained when RNA is extracted immediately after thawing are satisfactory, but decline very rapidly, beginning within 15 minutes, the larger variant transcripts being lost first and ultimately even the standard form.
- the diagnosis method described herein can be performed in a single day, possibly in a few hours, and is capable of being automated. Use of the method has been demonstrated, on various tissue samples to detect a whole variety of cancers, and also on blood and urine samples. We therefore offer it as a convenient practical method for cancer screening and diagnosis. In principle it could also have wide general applicability to cancer detection and prevention programmes and therefore have epidemiologic and public health value. Proper application of its sensitivity, specificity and simplicity should add not only to initial cancer diagnosis but to evaluation of extent of disease in the body, to judgment of the efficacy of treatment and to early detection of tumour recurrences.
- FIGURE LEGENDS
- N normal
- T primary tumour
- M metastasis
- Figure 1 Autoradiogram of PCR products from breast tissue samples probed with E4 (10 hours exposure of X- ray film to sample filter) .
- Panel A malignant primary breast carcinomas with their metastases. Tracks 1, 2 and 3: patient B1 ; tracks 4, 5 and 6: patient B2; tracks 7, 8 and 9: patient B3; tracks 10 and 11: patient B4; tracks 12 and 13: patient B5. It can be seen that compared to normal breast tissue, primary breast carcinomas and their metastatic deposits overexpress several splice-variants. Note the doublet (arrows) at 1500bp and 1650bp best seen in track 5. This is present in all tumours and metastases but is - 3 1 -
- Panel B Breast carcinomas with no clinical evidence of metastasis. Tracks 14-20 are from patients B15-B21. The tumours all overexpress several variants, but show less bands and the signal intensity is less, except track 16 (patient B17) - see text. The 1500/1650bp doublet (arrow) is easily recognisable in tracks 15, 16 and 18 at this length of exposure and became detectable in all other tumour-containing tracks on longer exposure. The illustration, however, shows only the shorter exposure, to avoid fogging the tracks which have stronger signals.
- Panel C Fibroadenomas (FA) and fibrocystic disease of the breast (Cyst). Tracks 21 and 22, containing the benign tumour samples (samples B22 and 23), express more than the non-neoplastic sample (fibrocystic disease) in track 23 (sample B24).
- tracks 4 and 5 were from individuals with no clinical evidence of neoplasia, as follows: track 4, breast tissue obtained at autopsy from the body of a woman who died of bacterial endocarditis; track 5, colon resected for volvulus.
- lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family. Cell 1989; 56: 1057-062.
- CD44 The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells. EMBO J. 1991; 10: 343-348.
- N-Fmoc-L-norleucine N-Fmoc-L-phenylalanme
- N-Fmoc-L-proline N-Fmoc-O-t-butyl-L-serine
- the ammo acid derivatives Prior to coupling, the ammo acid derivatives are dissolved in DMF and activated through the addition of 1 equivalent N-hydroxybenzotriazole (HOBt) in N- methylpyrrolid one (NMP) and 1 equivalent N,N ' - dicyclocarbodnmide (DCC) m NMP.
- HOBt N-hydroxybenzotriazole
- NMP N- methylpyrrolid one
- DCC N,N ' - dicyclocarbodnmide
- the 20-mmute couplings of the HOBt-ester amino acid are carried out in DMF.
- deprotection of the N- termini is achieved by a 3-m ⁇ nute and then a 10-m ⁇ nute treatment with 20% piperidme in DMF.
- the peptide chain is extended through repetition of the activation/couplmg/deprotection cycles.
- Peptides utilized later for immunogen synthesis are outfitted with an N-terminal am ocaproic acid spacer and cystein, through which the peptide is tethered to the carrier protein.
- N-terminal am ocaproic acid spacer and cystein through which the peptide is tethered to the carrier protein.
- a different N-terminus is synthesized and contains three gamma-aminobutyric acid moieties, lys e, and biotm (attached to the G-am o group of lys e) .
- TFA trifluoroacetic acid
- the peptide-beanng resin is reacted for 1 hour at room temperature (RT) with a cleavage cocktail containing 20 mL trifluoroacetic acid, 1 mL H2O, 1 mL thioanisole, 0.5 mL ethanedithiol and 1.5 g phenol. Removal of the acid-labile side-chain protecting groups, performed under Argon, is complete after an additional 2.4 h reaction time at RT in the aforementioned cocktail solution. After a brief cooling period, the deprotected peptide is precipitated through the addition of diisopropylether. The precipitate is filtered, washed with diisopropylether, dissolved in 50s acetic acid, frozen and lyophilized.
- a cleavage cocktail containing 20 mL trifluoroacetic acid, 1 mL H2O, 1 mL thioanisole, 0.5 mL ethanedithiol and 1.5 g phenol. Removal of the acid-
- Peptide purity is determined by reverse-phase HPLC (column - Vydac 218TP54, C 18 , 300 A, 5 ⁇ m, 4.6 x 250 mm; mobile phase - A: 0.1% TFA in H 2 0, B: 0.1% TFA in H 2 0/acetonitrile (35/65, v/v); gradient - 0-100% B in 90 min; flow rate - 1 mL/min; detection - 226 nm) .
- Those peptides being less than 60% pure are purified by reverse-phase HPLC (column - Waters DeltaPak C-g, 100 A, 15 ⁇ m, 50x300 mm; mobile phase - A: 0.1% TFA in H 2 0, B: 0.1% TFA in H 2 0/acetonitrile 35/65, v/v, gradient - 0.50% B in 130 min; flow rate - 15 mL/min; detection - 226 nm) .
- Peptide identity is verified by plasma desorption mass spectrometry. Characteristic HPLC retention times and mass spectral data for the peptides used for immunogen synthesis are listed in Table 2.
- a carrier protein either Keyhole Limpet Hemocyanin (KLH) or Bovine Serum Albumin (BSA)
- KLH Keyhole Limpet Hemocyanin
- BSA Bovine Serum Albumin
- MMS N-succinimidyl 3-maleimidopropionate
- thiol- containmg peptides are conjugated with the MP- activated carrier protein.
- BSA-MP a 74 ⁇ M BSA-Mp solution in 0.1 M KH 2 P0 4 /K 2 HP0 4 pH 7.0 is reacted with 1 equivalent (with respect to MP) of a 4 mM peptid solution in the same phosphate buffer. The solution is stirred slowly and allowed to react at RT overnight. After centrifugation, the soluble BSA-MP- peptide conjugate is separated from unbound peptide via size-exclusion chromatography (same chromatography conditions as given in section II).
- Analyses of the protein conjugate include protein concentration determination via BCA, as well as ascertaining the remaining number of unreacted MP-groups with Ellman ' s reagent.
- KLH-MP-peptide conjugates are synthesized similarly with the exception of activated carrier protein and peptide concentrations, which are 3 ⁇ M and 1 8 ⁇ M respectively.
- EXAMPLE 8 Manufacture of the recombinant HIV2 (gp32)-CD44 exon 6 antigen/imraunogen
- Exon 6 of the CD44 gene codes for a peptide of 43 amino acids as shown in Figure 7.
- the CD44 exon 6 antigen was duplicated at the DNA level using a suitable linker (codes for the 3 C-terminal amino acids of the exon 5 of CD44) .
- the molecular biological reagents were used according to the manufacturer's instructions.
- HIV2 (gp32)-partial gene Plasmid pUC18_HIV2-gp32
- the coding section of the amino acid 48-162 of the HIV2-gp32 gene was synthesized by overlapping chemical gene synthesis and subsequently subcloned in 4 4
- a fusion gene was constructed which codes for the N- terminal of the amino acid sequence MRGSHHHHHHTDPEF (poly-His tail) and the selected HIV2-g[32 antigen.
- the vector pQE-10 was digested with restriction endonucleases BamHI and Hindlll, and the approx. 3.4-kbp-long BamHI/HindIII-pQE-10 vector, fragment isolated by agarose gel electrophoresis.
- the pQE-10 vector [synonym: pDS56/RBSII, 6xHis(-1)] is sourced from Diagen, Germany, and is described in Stuber, D. et al. (1990) Immunol.
- Methods IV 121-152.
- the plasmid pUC18_HIV2-gp32 was digested by the restriction endonucleases BamHI and Hindlll, and the ca. 400-bp-long BamHI/HindIII-HIV2-gp32 fragment isolated and ligated into the approx. 3.4-bp-long BamHI/HindIII-pQE-10 vector fragment.
- the desired plasmid was identified by restriction mapping and designated pDS56-6HIS-HIV2-gp32.
- a fusion gene was constructed which codes N-terminal for the amino acid sequence MRGSHHHHHHTDPEF (poly-His tail), the selected HIV2-gp 32 antigen, and 2 copies of the CD44 exon 6 antigen.
- CD44 exon 5-6 DNA sequence from base pair position 397-538 was amplified (see Fig. 9: DNA sequence of HIV2 (gp32)-CD44 exon 6 fusion gene) and provided with suitable singular restriction endonuclease cleavage sites (BamHI and Haelll).
- CD44 cDNA Exon 5-11
- primer pair were used for amplification:
- the approx. 160-bp-long PCR product was digested with BamHI and Haelll and the approx. 150-bp- long BamHI/HaeIII-CD44 exon 6 fragment isolated by agarose gel electrophoresis.
- the CD44 exon 5-6 DNA sequence of base pair position 539-672 (see Fig. 9: DNA sequence of HIV2 (gp32) -CD44 exon 6 fusion gene) was amplified and provided with suitable singular restriction endonuclease cleavage sites (Haelll and Hindlll) using subcloned CD44 cDNA exon 5-11 as template DNA and the following primer pair:
- Haelll Primer (3) 5'-aaaaaaCCGGCCACCACTttgatgagcactagtgctac-3 '
- Hindlll Primer ( 4 ) 5 ' -aaaaaAA££IITTATCAagccatttgtgttgttgtgtgtg-3 - 46 -
- the approx. 150-bp-long PCR product was digested by Haelll and Hindlll and the approx. 140-bp- long BamHI/HaeIII-CD44 (Exon 6) fragment isolated by agarose gel electrophoresis. Then the BamHI/HaeII-CD44 exon 6 fragment from the first PCR reaction and the HaeIII/HindIII-CD44 exon 6 from the 2nd PCR reaction were ligated by 3- fragment ligation into an approx. 3.8-bp-long BgIII/HindIII-pDS56-6HIS-HIV2-gp32 vector fragment. The desired plasmid was identified by restriction mapping and the PCR-synthesised DNA regions checked by DNA sequencing (construction: pDS56-HIV2-CD44 exon 6).
- Gen. Genet. 150: 53-61) was transformed with the HIV2 (gp32) -CD44 exon 6 expression plasmid pDS56-HIV2-
- CD44 exon 6 resistance ampicillin
- IacI repressor plasmid pUHA1 resistance kanamycin
- RM82/pUHA1/pDS56-HIV2-CD44 exon 6 cells were cultured in DYT medium (1% (w/v) yeast extract, 1% ( w / v ) Bacto Tryptone, Difco, and 0.5% NaCl) with 50 mg/1 ampicillin and 50 mg/1 kanamycin up to an optical density of 0.6-0.9 at 550 nm, and then induced with IPTG (1-5 mmol/1 end concentration). After an induction phase of 4-8 h, the cells were harvested by centrifugation, washed with 10 mmol/1 phosphate buffer, pH 6.8, and stored at -20'C until further processing. - 4 7 -
- the cell pellet from 1 ml of culture medium (RM82/pUHA2/pDS56-HIV2-CD44 exon 6 cells) was re ⁇ suspended in 0.25 ml 10 mmol/1 phosphate buffer, pH 6.8, and 1 mmol/1 EDTA and the cells mechanically lysed by means of a French press. After centrifugation, 1/5 volumes of 5xSDS sample buffer: 50 mmol/1 Tris-HCl, pH 6.8, 1% SDS, 1% mercaptoethanol, 10% glycerol, and 0.001% bromophenol blue) was added to the supernatant. The insoluble cell debris fraction was resuspended in 0.3 ml 1xSDS sample buffer with 6-8 M urea.
- the expression level for the HIV2 (gp32) -CD44 exon 6 antigen was 30-50% in relation to the E.coli total protein.
- the insoluble components were then centrifuged down on a Sorvall centrifuge.
- the pellet was resuspended in 100 ml 0.1 mol/1 phosphate buffer, pH 8.5, incubated for 30 min at 25"C, and the IB product isolated by centrifugation.
- the 2.5 g IB pellet (wet weight) was suspended in 25 ml 6 mol/1 guanidine-HCl, 0.1 mol/1 phosphate buffer, pH 8.5, by stirring for 2 h at 25 C.
- the insoluble components were separated off by centrifugation and the clear supernatant applied to an NTA column equilibrated with 6 mol/1 guanidine-HCl, 0.1 mol/1 phosphate buffer, pH 8.5 (column volume: 50 ml, NTA gel from the Diagen Company, Germany; Hochuli, E. et al. (1988). Bio/Technology 6: 1321-1325).
- the column was then washed with about 5 column volumes of 8 mol/1 urea, 10 mmol/1 Tris-HCl, and 0- 1 mmol/1 phosphate buffer, pH 8.5. Subsequently, the HIV2 (gp32) -CD44 exon 6 antigen was eluted with 8 mol/1 urea and 0.1 mol/1 phosphate buffer, pH 4.0, and the HIV2(gp32)-CD44 exon 6 antigen-containing fractions pooled.
- HIV2 (gp32) carrier antigen was produced by using the plasmid pDS56-6HIS-HIV2-gp32.
- Biotinylation was performed with biotinoyl-*- aminocapronic acid-N-hydroxy- succinimide (Bi-X-NHS) (Boehringer Mannheim, Germany Cat. No. 1003933) in the molar ratios 1:3, 1:6, and 1:10.
- HIV2 (gp32)-CD44 exon 6 present in a concentration of 7.1 mg/ml in 8 M urea, 0.1 M sodium phosphate buffer, 10 mM Tris, pH ca. 6, was diluted with dialysis buffer (0.1 M sodium phosphate buffer, 0.5% SDS, 10 mM DTT, pH 8.5) to 2 mg/ml and dialyzed against the aforementioned dialysis buffer at room temperature and further diluted to 1 mg/ml.
- the appropriate quantity of Bi-X-NHS was added to the fusion protein, incubated for 2 h at room temperature, and than the reaction was stopped by addition of 1 M lysine/HCI, pH 6.5, to 2 mM. After dialysis against 0.1 M sodium phosphate buffer, 0.5% SDS, pH 6.0, the reagent HIV2 (gp32)-CD44 exon 6-Bi was stored at -20"C.
- the peptide HIV2. (gp32) was biotinylated analogous.
- mice Immunization of mice was performed according to Cianfriglia et al . (1983). Hybridoma, Vol. 2, No. 4: 451-457.
- immunogen synthetic peptides corresponding to am o acid 1 - 13, 9 - 23, 19 - 33, 29 - 43 and 1 - 43 coupled to a carrier protein (see example 7) as well as the HIV2 (gp32)-CD44 exon 6 antigen were used.
- mice were terminated by cervical dislocation, and their spleens removed under sterile conditions.
- the spleen cells were teased out of the connective tissue in RPMI 1640 basic medium.
- the cell suspension was then passed through a sieve and centrifuged at 200 g
- Hybridoma cells were multiplied over a period of 7 days at an inoculation density of 1 x 10 ⁇ cells/ml in RPMI 1640 +10% FCS on a'Techne biological stirrer (THERMO- DUX, Wertheim/Main, Model MCS-104XL, Cat. No. 144-050). Mean concentrations of 100 ⁇ g MAB/ml were achieved in the culture supernatant. Purification was performed using standard protein chemistry methods.
- HIV2(gp32) protein were obtained. These cultures were further assessed by dot-blot and imraunohistology.
- Method A Cells from tumor cell lines (e.g. ZR-75 1 or MDA 4A4) were detached from the flask by scraping and the cell suspensions were dropped onto glass slides, dried and fixed with methanol.
- tumor cell lines e.g. ZR-75 1 or MDA 4A4
- Method B Freeze-dried sections of tumor and normal tissue were fixed with acetone.
- the substrate was added and incubated with the sample (15-20 min). After washing with tap water the nuclei were stained with hematoxylin for 30 sec. The samples were dried and embeded with Cristal Mount (Kaiser ' s jelly).
- Cristal Mount Karl ' s jelly
- the results obtained with monoclonal antibody from cell lines MAB ⁇ CD44>M-1.1.12 and 4.3.16 are presented in Table 4.
- Method B the MAB 1.1.12 shows high specificity for tumor tissue from the lung, colon and bladder and MAB 4.3.16 revealed specificity for tumor tissue from the colon.
- MAB 1.1.12 and MAB 4.3.16 showed increased reactivity to - 55 -
- the cell line ZR-75-1 (exon 6 high-producer), a human breast cancer cell line (ATCC CRL 1500) than to the cell line MDA4A4 (exon 6 low-producer) .
- This cell iine is a subclone of cell line MDA-MB-435S (ductal carcinoma, breast, human; ATCC HTB 129; the subclone was produced according to Bao et al f Differentiation 52 (1993), 239-246; MDA4A4 is identical to MDA-MB-435-C2 of this reference) .
- the culture PK 9.00.22 showed a high specificity to tumor tissue of colon with method B. With method A this cultured cell line showed also a marked specificity for the ,cell line ZR 75-1.
- Cells of lines HT29 (ATCC HTB 38 - colon adenocarcinoma) and MDA4A4 were cultured in a medium according to ATCC catalogue and were harvested with or without protease additive.
- the cells harvested without protease additive were centrifuged, added to double the volume of lysis buffer (50 mM potassium phosphate buffer, 150 mM NaCl, pH 8.0), homogenised for 5 min in a Dounce homogenizer and the quantity of protein determined. On the basis of this protein value, the cellular suspension was adjusted to a protein concentration of 1-2 mg/ml using lysis buffer with or without detergent [1% Triton X-100 - 57 -
- the supernatant obtained after centrifuging off the membranes contained sufficient CD44 (standard form) and CD44v (CD44 with additional exons) for antibody assessment. Because of the mRNA concentration m the cells, it is assumed that MDA4A4 contains predominantly CD44-standard form and hardly any exon 6- containing CD44v. HT29 cells, on the other hand, should contain mainly exon 6- containing CD44v.
- CD44 or CD44v can be obtained is to harvest the cells with trypsin instead of the aforementioned cell harvest with subsequent cellular separation.
- the supernatant obtained after addition of trypsin inhibitor and centrifuging off the cells also contains sufficient CD44 and CD44v for antibody assessment.
- the specificity of the reaction can be shown by addition of free Exon6 peptide to the Ab before incubation of the nitrocellulose. If the reaction is specific for Exon6 or CD44v, either no or only very slight binding of the AB to the nitrocellulose takes place after addition of the free peptide. Best results were obtained with the following clones: * MAB ⁇ CD44>M-1.1.12 * MAB ⁇ CD44>M-2.42.3
- the antibodies produced by the cell lines MAK ⁇ CD44>M-1.1.12 and MAK ⁇ CD44>M-2.42.3 are able to bind to dotted CD44 exon 6 peptide and to an extract of 59
- HT29 cells but not to an extract of MDA4A4 cells. Binding of the monoclonal antibody to dotted CD44 exon 6 peptide and to an extract of HT29 ceils is specific for the tumorspecific variant of CD44v because preincubation of both antibodies with synthetic CD44 exon 6 inhibits the binding of the antibodies to nitrocellulose (Table 5) .
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP94900245A EP0672130A1 (fr) | 1992-11-20 | 1993-11-22 | Peptide correspondant a l'exon 6 du gene cd44, anticorps specifiques dudit peptide et utilisation de ces anticorps dans le diagnostic des tumeurs |
JP6512889A JPH08506801A (ja) | 1992-11-20 | 1993-11-22 | Cd44エキソン6に対応するペプチド、そのペプチドに特異的な抗体、および、腫瘍診断にそれらの抗体を使用する方法 |
US08/428,138 US5879898A (en) | 1992-11-20 | 1993-11-22 | Antibodies specific for peptide corresponding to CD44 exon 6, and use of these antibodies for diagnosis of tumors |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929224386A GB9224386D0 (en) | 1992-11-20 | 1992-11-20 | Nucleic acid sequence |
GB9224386.4 | 1992-12-16 | ||
GB9226165.0 | 1992-12-16 | ||
GB929226165A GB9226165D0 (en) | 1992-12-16 | 1992-12-16 | Nucleic acid sequence |
PCT/GB1993/001520 WO1994002633A1 (fr) | 1992-07-21 | 1993-07-20 | Methode de diagnostic |
ATPCT/GB93/01520 | 1993-07-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994012631A1 true WO1994012631A1 (fr) | 1994-06-09 |
Family
ID=27266472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1993/002394 WO1994012631A1 (fr) | 1992-11-20 | 1993-11-22 | Peptide correspondant a l'exon 6 du gene cd44, anticorps specifiques dudit peptide et utilisation de ces anticorps dans le diagnostic des tumeurs |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0672130A1 (fr) |
JP (1) | JPH08506801A (fr) |
CA (1) | CA2149635A1 (fr) |
WO (1) | WO1994012631A1 (fr) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995033771A1 (fr) * | 1994-06-08 | 1995-12-14 | Boehringer Ingelheim International Gmbh | Anticorps monoclonal actif contre le cd44v6 |
WO1997016557A1 (fr) * | 1995-10-31 | 1997-05-09 | Boehringer Ingelheim International Gmbh | TRAITEMENT DE TUMEURS PAR TRANSFERT ADOPTIF DE LYMPHOCYTES T CYTOTOXIQUES SPECIFIQUES DU CD44v |
DE19545472A1 (de) * | 1995-12-06 | 1997-06-12 | Boehringer Ingelheim Int | Verfahren zur Diagnose und Therapie von Plattenepithelkarzinomen |
EP0881299A1 (fr) * | 1996-02-15 | 1998-12-02 | Chugai Seiyaku Kabushiki Kaisha | Anticorps monoclonal reconnaissant les antigenes presents a la surface des cellules endotheliales d'un vaisseau tumoral |
WO1999004036A1 (fr) * | 1997-07-14 | 1999-01-28 | Isis Innovation Limited | Detection de cancer a base de cd44 |
WO1999046403A1 (fr) * | 1998-03-11 | 1999-09-16 | Exonhit Therapeutics S.A. | Criblage differentiel qualitatif |
US6372441B1 (en) | 1996-12-20 | 2002-04-16 | Forschungszentrum Karlsruhe Gmbh | Method for diagnosis and therapy of Hodgkin's lymphomas |
WO2002094879A1 (fr) * | 2001-05-18 | 2002-11-28 | Boehringer Ingelheim International Gmbh | Anticorps specifiques contre cd44v6 |
US6881571B1 (en) | 1998-03-11 | 2005-04-19 | Exonhit Therapeutics S.A. | Qualitative differential screening |
US6972324B2 (en) | 2001-05-18 | 2005-12-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Antibodies specific for CD44v6 |
US7189397B2 (en) * | 1999-10-08 | 2007-03-13 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US7507537B2 (en) | 1999-10-08 | 2009-03-24 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US7947496B2 (en) | 1999-10-08 | 2011-05-24 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US8048416B2 (en) | 1999-10-08 | 2011-11-01 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US8071072B2 (en) | 1999-10-08 | 2011-12-06 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
WO2012028523A3 (fr) * | 2010-08-30 | 2012-04-26 | F. Hoffmann-La Roche Ag | Construction d'expression procaryote |
-
1993
- 1993-11-22 EP EP94900245A patent/EP0672130A1/fr not_active Withdrawn
- 1993-11-22 JP JP6512889A patent/JPH08506801A/ja active Pending
- 1993-11-22 WO PCT/GB1993/002394 patent/WO1994012631A1/fr not_active Application Discontinuation
- 1993-11-22 CA CA002149635A patent/CA2149635A1/fr not_active Abandoned
Non-Patent Citations (7)
Title |
---|
"8th INTERNATIONAL CONGRESS OF IMMUNOLOGY, Budapest, Hungary, August 23-28, 1992", August 1992, SPRINGER VERLAG, BUDAPEST * |
G. SCREATON ET AL.: "Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 89, no. 24, 15 December 1992 (1992-12-15), WASHINGTON DC, USA, pages 12160 - 12164, XP000470187 * |
M. SALMI ET AL.: "Regulated expression of exon v6 containing isoforms of CD44 in man: Downregulation during malignant transformation of tumors of squamocellular origin.", THE JOURNAL OF CELL BIOLOGY, vol. 122, no. 2, July 1993 (1993-07-01), NEW YORK, USA, pages 431 - 442, XP000197159, DOI: doi:10.1083/jcb.122.2.431 * |
R. ARCH ET AL.: "Participation in normal immune responses of metastasis-inducing splice variant of CD44.", SCIENCE, vol. 257, no. 5070, 31 July 1992 (1992-07-31), WASHINGTON DC, USA, pages 682 - 685, XP000918839, DOI: doi:10.1126/science.1496383 * |
S. REBER ET AL.: "Retardation of metastatic tumor growth after immunization with metastasis-specific monoclonal antibodies.", INTERNATIONAL JOURNAL OF CANCER, vol. 46, no. 5, 15 November 1990 (1990-11-15), GENEVA, SWITZERLAND, pages 919 - 927, XP009124496, DOI: doi:10.1002/ijc.2910460528 * |
S. SEITER ET AL.: "Expression of variant CD44 transfers the metastatic phenotype and antibodies against variant CD44 inhibit metastatic spread in lymphatic tissue.", IMMUNOBIOLOGY, vol. 183, no. 3/4, October 1991 (1991-10-01), STUTTGART, GERMANY, pages 221 - 222 * |
Y. MATSUMURA ET AL.: "Significance of CD44 gene products for cancer diagnosis and disease evaluation.", THE LANCET, vol. 340, no. 8827, 31 October 1992 (1992-10-31), LONDON, GB, pages 1053 - 1058, XP001055930, DOI: doi:10.1016/0140-6736(92)93077-Z * |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5916561A (en) * | 1994-06-08 | 1999-06-29 | Boehringer Ingelheim International Gmbh | Monoclonal antibody against CD44v6 |
WO1995033771A1 (fr) * | 1994-06-08 | 1995-12-14 | Boehringer Ingelheim International Gmbh | Anticorps monoclonal actif contre le cd44v6 |
WO1997016557A1 (fr) * | 1995-10-31 | 1997-05-09 | Boehringer Ingelheim International Gmbh | TRAITEMENT DE TUMEURS PAR TRANSFERT ADOPTIF DE LYMPHOCYTES T CYTOTOXIQUES SPECIFIQUES DU CD44v |
DE19545472A1 (de) * | 1995-12-06 | 1997-06-12 | Boehringer Ingelheim Int | Verfahren zur Diagnose und Therapie von Plattenepithelkarzinomen |
EP0881299A1 (fr) * | 1996-02-15 | 1998-12-02 | Chugai Seiyaku Kabushiki Kaisha | Anticorps monoclonal reconnaissant les antigenes presents a la surface des cellules endotheliales d'un vaisseau tumoral |
US7189824B2 (en) | 1996-02-15 | 2007-03-13 | Chugai Seiyaku Kabushiki Kaisha | Tumor vessel endothelial cell-binding monoclonal antibodies |
EP0881299A4 (fr) * | 1996-02-15 | 2004-12-15 | Chugai Seiyakukabushiki Kaisha | Anticorps monoclonal reconnaissant les antigenes presents a la surface des cellules endotheliales d'un vaisseau tumoral |
US6372441B1 (en) | 1996-12-20 | 2002-04-16 | Forschungszentrum Karlsruhe Gmbh | Method for diagnosis and therapy of Hodgkin's lymphomas |
WO1999004036A1 (fr) * | 1997-07-14 | 1999-01-28 | Isis Innovation Limited | Detection de cancer a base de cd44 |
US6881571B1 (en) | 1998-03-11 | 2005-04-19 | Exonhit Therapeutics S.A. | Qualitative differential screening |
WO1999046403A1 (fr) * | 1998-03-11 | 1999-09-16 | Exonhit Therapeutics S.A. | Criblage differentiel qualitatif |
US6251590B1 (en) | 1998-03-11 | 2001-06-26 | Exonhit Therapeutics S.A. | Differential Qualitative screening |
FR2775984A1 (fr) * | 1998-03-11 | 1999-09-17 | Bioscreen Therapeutics Sa | Criblage differentiel qualitatif |
US8003375B2 (en) | 1998-03-11 | 2011-08-23 | Exonhit Therapeutics S.A. | Qualitative differential screening |
US7947496B2 (en) | 1999-10-08 | 2011-05-24 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US7189397B2 (en) * | 1999-10-08 | 2007-03-13 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US7507537B2 (en) | 1999-10-08 | 2009-03-24 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US8017117B2 (en) | 1999-10-08 | 2011-09-13 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US8048416B2 (en) | 1999-10-08 | 2011-11-01 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US8071072B2 (en) | 1999-10-08 | 2011-12-06 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US8388961B2 (en) | 1999-10-08 | 2013-03-05 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US7417127B2 (en) | 2001-05-18 | 2008-08-26 | Boehringer Ingelheim Pharmaceuticals, Inc. | Antibodies specific for CD44v6 |
WO2002094879A1 (fr) * | 2001-05-18 | 2002-11-28 | Boehringer Ingelheim International Gmbh | Anticorps specifiques contre cd44v6 |
US6972324B2 (en) | 2001-05-18 | 2005-12-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Antibodies specific for CD44v6 |
WO2012028523A3 (fr) * | 2010-08-30 | 2012-04-26 | F. Hoffmann-La Roche Ag | Construction d'expression procaryote |
CN103025875A (zh) * | 2010-08-30 | 2013-04-03 | 霍夫曼-拉罗奇有限公司 | 原核表达构建体 |
US8877895B2 (en) | 2010-08-30 | 2014-11-04 | Hoffmann-La Roche Inc. | Prokaryotic expression construct |
Also Published As
Publication number | Publication date |
---|---|
CA2149635A1 (fr) | 1994-06-09 |
JPH08506801A (ja) | 1996-07-23 |
EP0672130A1 (fr) | 1995-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5879898A (en) | Antibodies specific for peptide corresponding to CD44 exon 6, and use of these antibodies for diagnosis of tumors | |
JP4229591B2 (ja) | 前立腺特異的膜抗原の細胞外ドメインに対して特異的なモノクローナル抗体 | |
JP4295826B2 (ja) | 前立腺特異的膜抗原の細胞外ドメインに対して特異的なモノクローナル抗体 | |
CA2259421C (fr) | Marquage et selection de molecules | |
US5489525A (en) | Monoclonal antibodies to prostate cells | |
AU683413B2 (en) | Antibodies specific for carcinoma-associated antigens | |
EP2913673B1 (fr) | Diagnostic du carcinome de l'ovaire | |
US5965710A (en) | Monoclonal antibodies for use in diagnosis and treatment of colorectal cancer | |
AU773568B2 (en) | Antobody to human gastrointestinal epithelial tumor antigen related to alpha 6 beta 4 integrin | |
KR100379217B1 (ko) | CD44v6에대한모노클로날항체 | |
WO1994012631A1 (fr) | Peptide correspondant a l'exon 6 du gene cd44, anticorps specifiques dudit peptide et utilisation de ces anticorps dans le diagnostic des tumeurs | |
US20140294845A1 (en) | Anti-pleiotrophin antibodies and methods of use thereof | |
KR19990087802A (ko) | 전립선암의 면역치료 및 면역진단을 위한 화합물 및 방법 | |
US20030082188A1 (en) | Treatment of prostate cancer by inhibitors of NCAM2 | |
JP2011206062A (ja) | 癌を診断するための方法および組成物 | |
KR20130135402A (ko) | 종양에서 특이적으로 발현되는 유전 산물 및 그의 용도 | |
KR100189046B1 (ko) | 종양-관련 항원에 대한 모노클로날 항체의 가변성 도메인의 폴리펩타이드 | |
JP4695982B2 (ja) | 肝癌の検出方法及び肝癌診断薬並びに癌治療薬 | |
CN114853890A (zh) | 一种prlr抗原结合蛋白及其制备方法和应用 | |
WO2011091716A1 (fr) | Variante du récepteur du facteur de croissance épidermique | |
JPH05317088A (ja) | 腫瘍関連抗原に対するモノクローナル抗体、その製造方法およびその使用 | |
US7491801B2 (en) | Identification and development of specific monoclonal antibodies to squamous cell carcinoma | |
US6013495A (en) | Methods of use for integrin B1C cell growth inhibitor | |
WO2006057623A1 (fr) | Anticorps runx3 et procede de collecte | |
US20110104675A1 (en) | Methods and Compositions for Diagnosing Carcinomas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 1995 373284 Country of ref document: US Date of ref document: 19950407 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1994900245 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2149635 Country of ref document: CA Ref document number: 08428138 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1994900245 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994900245 Country of ref document: EP |